Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Myelodysplastic Syndromes 1

Interventions

pembrolizumab 4Radiotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Temozolomide 2Paclitaxel 2Ipilimumab 2Fluorodeoxyglucose F18 2Cyclophosphamide 2Carboplatin 2temsirolimus 1sugemalimab 1semaglutide 1sacituzumab govitecan 1prednylidene 1pirtobrutinib 1paricalcitol 1pamiparib 1olaparib 1mirdametinib 1gadobutrol 1fludarabine phosphate 1fludarabine 1erdafitinib 1enfortumab vedotin 1dupilumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1daratumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Decitabine × 30 days × Clear all
NCT04187703 2026-05-18

5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Recruiting
20 enrolled
Myeloid

Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡